CPA3 and mastocytosis: Also, that mastocytosis is a growing conjoint of diseases [41] that gives rise, among others, to massive extracellular release of carboxypeptidase A3 from degranulated mastocytes, constituting a potential therapeutic target for carboxypeptidase inhibitors [42].